Drug Profile
Research programme: abuse-resistant opioid analgesics - DURECT Corporation
Alternative Names: Abuse-resistant oxymorphone; ORADUR-OxymorphoneLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator DURECT Corporation
- Class Morphine derivatives; Opioid analgesics
- Mechanism of Action Opioid mu receptor agonists; Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Pain(Abuse-resistant) in USA (PO, Capsule)
- 13 Jul 2017 Preclinical trials in Pain (Abuse-resistant) in USA (PO) (DURECT Corporation pipeline, July 2017)
- 16 Nov 2013 Suspended - Preclinical for Pain in USA (PO)